Table 2. Baseline demographics and specific clinical characteristics (FAS population).
| Characteristic | Fosaprepitant regimen (n=321) | Aprepitant regimen (n=323) | P value |
|---|---|---|---|
| Gender, n (%) | |||
| Male | 191 (59.50) | 191 (59.13) | 0.9362 |
| Female | 130 (40.50) | 132 (40.87) | |
| Age, years | |||
| Mean ± SD | 55.88±10.37 | 55.88±10.19 | 0.9993a |
| Range | 18–75 | 25–75 | |
| ECOG PS, n (%) | |||
| 0 | 104 (32.40) | 111 (34.37) | 0.3487b |
| 1 | 204 (63.55) | 207 (64.09) | |
| 2 | 13 (4.05) | 5 (1.55) | |
| Initial treatment with chemotherapy, n (%) | 217 (67.60) | 211 (65.33) | 0.5597 |
| History of cancer treatment, n (%) | 175 (54.52) | 176 (54.49) | 1.0000 |
| History of alcohol use, n (%) | 88 (27.41) | 76 (23.53) | 0.2782 |
| History of motion sickness, n (%) | 19 (5.92) | 9 (2.79) | 0.0553 |
| History of vomiting during pregnancy*, n (%) | 47 (14.64) | 52 (16.15) | 0.7544 |
| History of vomiting during anti-tumor treatment, n (%) | 59 (18.38) | 71 (21.98) | 0.2805 |
| History of drug allergy, n (%) | 23 (7.17) | 24 (7.43) | 1.0000 |
*, only female patients were considered for vomiting during pregnancy; a, t test, t=0.00; b, Z test, z=0.94. SD, standard deviation; NA, not applicable; FAS, full analysis set.